Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
Trial details
- Registry ID
- NCT02032004
- Drugs studied
- Rexlemestrocel-L, Sham Comparator
TrialRedline tracks 8 clinical trials sponsored by Mesoblast, Inc.: 4 Phase 3, 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart FailureNCT02032004 | Rexlemestrocel-L, Sham Comparator | Completed | 2020-01-30Actual |
| Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseNCT00482092 | Prochymal® | Completed | 2014-09-15Actual |
| Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseNCT01233960 | Prochymal® | Completed | 2014-09-15Actual |
| Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseNCT00543374 | PROCHYMAL adult human mesenchymal stem cells | Completed | 2009-07Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)NCT00877903 | Prochymal® | Completed | 2011-05-18Actual |
| PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)NCT00690066 | PROCHYMAL® | Completed | 2010-12-12Actual |
| PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00683722 | Prochymal™ | Completed | 2009-03-09Actual |
| Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsNCT00284986 | Prochymal | Completed | 2006-04-25Actual |
Names as written in the registry records.
NCT02032004 · Mesoblast, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).. After: Measure: Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE).
Before: 566 participants (actual). After: 565 participants (actual).
Before: 29 May 2020. After: 30 Jan 2020.